ArticleCureus2025
Sertraline-Induced Bradycardia: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for depression and several psychiatric disorders due to their effectiveness and tolerability. However, they can cause cardiovascular side effects, particularly bradycardia, raising safety concerns. SSRI-induced bradycardia occurs through serotonin's effects on autonomic and cardiovascular regulation. SSRIs impact cardiac conduction by modulating serotonin receptors and inhibiting sodium and calcium channels, leading to varied bradycardia presentations. This case report indicates the occurrence of bradycardia in a 63-year-old male patient after an increasing dose of sertraline, an SSRI. The patient exhibited symptoms of bradycardia (heart rate of 46 bpm) along with headache and dizziness. The patient also had a medical history of hypothyroidism and hyperlipidemia. The pharmacological intervention involved gradually increasing the dose of sertraline from 25 mg to 50 mg daily to optimize the treatment of depression, while bradycardia persisted. A switch to escitalopram and dose adjustments of levothyroxine did not resolve the issue. Ultimately, the bradycardia resolved after switching to bupropion. This contrasts with previous reports where elderly patients experienced rapid resolution of bradycardia after discontinuation of SSRIs. Our patient exhibited bradycardia as opposed to severe outcomes reported in other studies, further showing the unique nature of this case. The study highlights the significant increase in mortality risk due to cardiovascular side effects associated with psychiatric medications. While SSRIs are generally regarded as safer compared to other antidepressants, previous literature reviews indicate a notable potential for cardiovascular side effects. The literature review examines various databases and reports that while citalopram, escitalopram, and fluoxetine have been linked to bradycardia at elevated doses, there is limited evidence directly connecting sertraline to this condition. This study concludes by emphasizing the need for careful monitoring and consideration of various factors, such as age, ethnicity, and the potential for polypharmacy, when prescribing SSRIs. The findings underscore the necessity for further research to elucidate the relationship between sertraline and bradycardia and inform clinical management strategies for this adverse reaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.